Abstract:Chromatographic separation serves as "a workhorse" for downstream process development and plays a key role in the removal of product-related, host-cell-related, and process-related impurities. Complex and poorly characterized raw materials and feed material, low feed concentration, product instability, and poor mechanistic understanding of the processes are some of the critical challenges that are faced during the development of a chromatographic step. Traditional process development is performed as a trial-and-error-based evaluation and often leads to a suboptimal process. A high-throughput process development (HTPD) platform involves the integration of miniaturization, automation, and parallelization and provides a systematic approach for time- and resource-efficient chromatographic process development. Creation of such platforms requires the integration of mechanistic knowledge of the process with various statistical tools for data analysis. The relevance of such a platform is high in view of the constraints with respect to time and resources that the biopharma industry faces today.This protocol describes the steps involved in performing the HTPD of chromatography steps. It describes the operation of a commercially available device (PreDictor™ plates from GE Healthcare). This device is available in 96-well format with 2 or 6 μL well size. We also discuss the challenges that one faces when performing such experiments as well as possible solutions to alleviate them. Besides describing the operation of the device, the protocol also presents an approach for statistical analysis of the data that are gathered from such a platform. A case study involving the use of the protocol for examining ion exchange chromatography of the Granulocyte Colony Stimulating Factor (GCSF), a therapeutic product, is briefly discussed. This is intended to demonstrate the usefulness of this protocol in generating data that are representative of the data obtained at the traditional lab scale. The agreement in the data is indeed very significant (regression coefficient 0.93). We think that this protocol will be of significant value to those involved in performing the high-throughput process development of the chromatography process.

Integrated micro‐scale protein a chromatography and Low pH viral inactivation unit operations on an automated platform

UV/Vis-based process analytical technology to improve monoclonal antibody and host cell protein separation

Analysis and Optimal Design of Batch and Two‐column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Converting a Mab Downstream Process from Batch to Continuous Using Process Modeling and Process Analytical Technology.

A tandem laboratory scale protein purification process using Protein A affinity and anion exchange chromatography operated in a weak partitioning mode

Integrated continuous downstream process of monoclonal antibody developed by converting the batch platform process based on the process characterization

Developing the biofacility of the future based on continuous processing and single-use technology

Technical Optimization for the High-Throughput Purification of Antibodies on Automated Liquid Handlers

Viral inactivation for pH-sensitive antibody formats such as multi-specific antibodies

Real‐Time Adaptive Inline Acidification Enhances Continuous pH Control for Viral Inactivation

Digital Twin in High Throughput Chromatographic Process Development for Monoclonal Antibodies

Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays.

Development of temperature-controlled batch and 3-column counter-current protein A system for improved therapeutic purification

Optimizing high throughput antibody purification by using continuous chromatography media

High-Throughput Process Development: I-Process Chromatography

Development of a robust and semi-automated two-step antibody purification process

Virus study for continuous low pH viral inactivation inside a coiled flow inverter

Downstream processing of virus, virus-like particles and nanoparticulate inclusion bodies to be used as gene delivery vehicles for human gene therapy applications

A Model-Based Performance Analysis of Integrated Chromatography-Ultrafilter Separation Systems for Monoclonal Antibody (mAb) Manufacturing

Online multimethod platform for comprehensive characterization of monoclonal antibodies in cell culture fluid from a single sample injection - Intact protein workflow

Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics